Cite
Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.
MLA
Oomen, Ilja, et al. “Anti-Rituximab Antibodies Affect Pharmacokinetics and Pharmacodynamics of Rituximab in Children with Immune-Mediated Diseases.” Clinical and Experimental Rheumatology, vol. 40, no. 1, Jan. 2022, pp. 183–90. EBSCOhost, https://doi.org/10.55563/clinexprheumatol/ftira8.
APA
Oomen, I., Nassar-Sheikh Rashid, A., Bouts, A. H. M., Gouw, S. C., Kuijpers, T. W., Rispens, T., de Vries, A., Wolbink, G., van den Berg, J. M., & Schonenberg-Meinema, D. (2022). Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. Clinical and Experimental Rheumatology, 40(1), 183–190. https://doi.org/10.55563/clinexprheumatol/ftira8
Chicago
Oomen, Ilja, Amara Nassar-Sheikh Rashid, Antonia H M Bouts, Samantha C Gouw, Taco W Kuijpers, Theo Rispens, Annick de Vries, Gertjan Wolbink, J Merlijn van den Berg, and Dieneke Schonenberg-Meinema. 2022. “Anti-Rituximab Antibodies Affect Pharmacokinetics and Pharmacodynamics of Rituximab in Children with Immune-Mediated Diseases.” Clinical and Experimental Rheumatology 40 (1): 183–90. doi:10.55563/clinexprheumatol/ftira8.